Harnessing breakthroughs in brown fat and insulin sensitization A scientific breakthrough of one of Ember’s co-founders uncovered a novel hormone, irisin. Ember has exclusively licensed this irisin technology. New research provided a mechanistic understanding of how novel selective insulin sensitizers could produce anti-diabetic effects. The rising epidemics of Type 2 diabetes and obesity urgently demand a new class of treatments with improved safety profiles.

Ember Therapeutics is a product-focused company translating its world-class biology in the emerging area of brown fat and recent breakthroughs in understanding the mechanisms of selective insulin sensitivity into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity.

 

10.04.12
Ember Therapeutics Broadens Brown Fat Small Molecule Drug Discovery Portfolio, Secures Exclusive License Options to Intellectual Property for Three Small Molecule Targets Read More